Celularity Inc. (NASDAQ:CELU - Get Free Report) was up 7.4% on Tuesday . The stock traded as high as $2.33 and last traded at $2.33. Approximately 79,403 shares changed hands during trading, a decline of 76% from the average daily volume of 332,284 shares. The stock had previously closed at $2.17.
Analysts Set New Price Targets
Separately, Wall Street Zen cut Celularity from a "hold" rating to a "sell" rating in a report on Thursday.
Get Our Latest Stock Analysis on Celularity
Celularity Stock Performance
The company has a market capitalization of $54.84 million, a price-to-earnings ratio of -0.86 and a beta of 0.61. The company's fifty day simple moving average is $1.73 and its two-hundred day simple moving average is $2.01.
Celularity (NASDAQ:CELU - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.91. Celularity had a negative net margin of 72.72% and a negative return on equity of 119.53%. The business had revenue of $18.13 million for the quarter, compared to analyst estimates of $5.20 million.
Institutional Trading of Celularity
A number of hedge funds have recently modified their holdings of the company. Keynote Financial Services LLC lifted its position in shares of Celularity by 90.1% during the fourth quarter. Keynote Financial Services LLC now owns 25,023 shares of the company's stock worth $52,000 after purchasing an additional 11,863 shares in the last quarter. C V Starr & Co. Inc. bought a new position in shares of Celularity during the 4th quarter worth approximately $1,589,000. Biltmore Family Office LLC bought a new stake in Celularity during the 4th quarter worth about $73,000. Two Sigma Investments LP bought a new stake in shares of Celularity during the 4th quarter worth approximately $93,000. Finally, Acadian Asset Management LLC acquired a new stake in Celularity in the first quarter valued at $34,000. Institutional investors own 19.02% of the company's stock.
About Celularity
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Featured Stories
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
